Sarepta therapeutics to share new clinical data and integrated analysis for srp-9001, its investigational gene therapy for the treatment of duchenne muscular dystrophy on july 6, 2022 at 8:30am et

Cambridge, mass., july 05, 2022 (globe newswire) -- sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced that on wednesday, july 6, 2022 at 8:30am eastern time, the company will host a webcast and conference call to share new functional data across multiple studies from the clinical development program for srp-9001 (delandistrogene moxeparvovec) for the treatment of duchenne muscular dystrophy. the company also plans to present an integrated analysis of one-year functional data from studies 101, 102 and 103 for all participants that received the target dose of srp-9001 compared to a propensity-weighted external control group. srp-9001 is an investigational gene therapy for duchenne being developed in partnership with roche.
SRPT Ratings Summary
SRPT Quant Ranking